Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook

Goldman Sachs reiterated its Buy rating and $19.00 price target for Carlsmed Inc. (CARL) after the company reported a robust 99% year-over-year revenue increase to $12.1 million in Q2, exceeding its full-year outlook. The firm expressed strong confidence in CARL's growth trajectory and financial health, noting the company's current ratio of 6.48 and sufficient capital from a recent raise to achieve positive adjusted EBITDA and cash flow without additional financing, signaling significant upside potential from its current $13.69 share price.

Analysis

Goldman Sachs has reaffirmed its bullish stance on Carlsmed Inc. (CARL) by reiterating a Buy rating and a $19.00 price target, which suggests significant upside from the current price of $13.69. This confidence is underpinned by the company's robust second-quarter 2025 performance, which featured a 99% year-over-year revenue increase to $12.1 million. The company's full-year outlook was also raised above expectations, driven by a higher-than-anticipated rate of surgeon additions in Q2, a key leading indicator for future revenue. Financially, Carlsmed exhibits a strong balance sheet, evidenced by a current ratio of 6.48 and moderate debt levels. Critically, Goldman Sachs' analysis indicates that a recent capital raise provides sufficient funding for the company to achieve positive adjusted EBITDA and cash flow without the need for additional financing, mitigating a common risk for growth-stage companies. The firm's Street-high revenue estimates further signal a conviction that Carlsmed's growth trajectory may be underappreciated by the broader market.

Key Decisions for Investors

• Investors with a growth-oriented mandate should consider the stock favorably, given the potent combination of accelerating revenue, an upgraded full-year outlook, and a strong endorsement from a major investment bank.
• Monitor future reports for data on surgeon additions, as this operational metric is the primary driver behind the current revenue outperformance and revised guidance.
• The assertion that the company is fully funded to profitability is a core tenet of the bull case; therefore, investors should closely track quarterly cash burn and progress towards positive adjusted EBITDA to validate this thesis.